Axitinib and Cabozantinib in the Treatment  of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC)...

Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC)...

User Photo
kidneycancer

2 years
774 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis of AXIS and METEOR Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.
Up Next Autoplay
User Photo